organogenesis
-
Financial
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Financial
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Financial
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Biologics
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Financial
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance
CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Biologics
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with…
Read More » -
Financial
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020
CANTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Biologics
Organogenesis Holdings Inc. Announces Management Change
CANTON, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Financial
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Biologics
Organogenesis Announces Virtual Education Events for April
CANTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development,…
Read More » -
Financial
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results
CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…
Read More » -
Extremities
Organogenesis Comparative Effectiveness Research Demonstrating Faster VLU Time to Healing with Apligraf® Showcased at ISPOR
CANTON, Mass. and BALTIMORE, May 31, 2018 /PRNewswire/ — New comparative effectiveness research from Organogenesis Inc. demonstrating faster time to healing and greater healing rates…
Read More » -
Biologics
Organogenesis Showcases New Product Offerings and Research at SAWC Spring 2018
CANTON, Mass. and CHARLOTTE, N.C., April 24, 2018 /PRNewswire/ — The latest advanced wound care research and product offerings from Organogenesis Inc. – including the…
Read More » -
Biologics
Organogenesis Names New Chief Commercial Officer and Chief Operating Officer
CANTON, Mass., Sept. 19, 2017 /PRNewswire/ — Organogenesis Inc., a commercial leader in the field of regenerative medicine with a portfolio of advanced…
Read More » -
Biologics
PuraPly™ Antimicrobial Named One of Top 10 Innovations in Podiatry
CANTON, Mass., July 13, 2017 /PRNewswire/ — PuraPlyTM Antimicrobial (PuraPlyTM AM), an FDA 510(k)-cleared wound management product from Organogenesis Inc., has been named one of…
Read More »